Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start Up Spotlight: SurgiMab Aims For First-In-Market Tumor-Detecting Fluorescent Probe For FGS

Executive Summary

SurgiMab is aiming for its lead product, SGM-101, to be the first tumor-targeted fluorescent probe to be marketed for fluorescence-guided surgery (FGS). Based in Montpellier, France, the company has initiated a Phase III trial to assess the clinical benefit of using FGS with SGM-101 as the intraoperative imaging agent to identify cancer lesions during colorectal surgery.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT125408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel